Xin (Sheen) Xu
Lawyers
Filters
Pony AI HK$6.71 billion dual primary listing on the Hong Kong Stock Exchange
We advised Pony AI on its dual primary listing on HKEX
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Adagene $25 million strategic equity investment from Sanofi
We advised Adagene on the transaction
VNET Group $430 million convertible senior notes offering
We advised VNET Group on the transaction
Chagee $411.2 million IPO
We advised Chagee on its IPO and Nasdaq listing
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Mongolian Mining tap notes issuance
We advised Mongolian Mining on the issuance of additional 12.5% senior notes due 2026
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction